Delving into the Latest Updates on Parecoxib Sodium with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

N-((p-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)propionamide, parecoxib, Parecoxib sodium (USAN)

+ [8]

Target

COX-2

Action

inhibitors

Mechanism

COX-2 inhibitors(Cyclooxygenase-2 inhibitors)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

Pain, Postoperative

Inactive Indication

ColicRenal Colic

Originator Organization

Pfizer Inc.

Active Organization

Pfizer Europe MA EEIG

Pfizer Australia Pty Ltd.

Pfizer Inc.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

European Union (22 Mar 2002),

Pain, Postoperative

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC19H18N2NaO4S

InChIKeyIMBMHWVEMVJSIQ-UHFFFAOYSA-N

CAS Registry198470-85-8

Introduction: This study focuses on the treatment of painful crises in Sickle Cell Disease (SCD) patients using Paracoxib, a non-opioid, compared to Morphine. It addresses the need for alternative medications that reduce opioid dependency while providing effective analgesia.
Objectives:
Primary: Evaluate the analgesic effect of Paracoxib versus Morphine in SCD vaso-occlusive crises.
Secondary: Reduce opioid use/dependence, decrease the length of hospital stays, and monitor side effects related to Paracoxib.
Methodology: A double-blinded randomized controlled trial, conducted in a tertiary care emergency department. The study includes adult SCD patients with moderate to severe crises, excluding non-VOC pain, certain medications, and specific medical conditions. The sample size is 226 patients, split equally into two groups.
Intervention: Patients receive either Morphine or Paracoxib, with periodic assessment of vital signs and pain. Additional Morphine is administered if required. Data collection and analysis are meticulously planned.
Expected Outcomes: Improvement in SCD pain management, reduction in opioid usage, and potential benefits in terms of hospital stays and patient satisfaction.

Start Date01 May 2026

Sponsor / Collaborator

Armed Forces Hospital

ChiCTR2500095107

/ SuspendedNot ApplicableIIT

Effect of esketamine combined with parecoxib sodium on postoperative analgesia and inflammatory response in patients with thoracoscopic pulmonary resection

Start Date05 Jan 2025

Sponsor / Collaborator-

NCT06579274

/ Not yet recruitingPhase 2IIT

A Randomized, Placebo-controlled, Double-blind Clinical Trial Evaluating the Safety and Efficacy of Parecoxib in Hospitalized Patients With Spontaneous Subarachnoid Hemorrhage

Because of the important role of inflammation in the pathophysiology of SAH, it was hypothesized that its pharmacological manipulation might improve the prognosis of patients. In recent years, the effects of several groups of anti-inflammatory drugs on the development of complications after SAH have been described. Initially promising, glucocorticoids, thought to reduce cerebrovascular inflammation, brain swelling, and headache, failed in clinical trials. Studies have not provided clear evidence of the beneficial effects of these drugs in patients after SAH. Therefore, the administration of glucocorticoids is not currently part of the recommended practice. In addition, glucocorticoid treatment is associated with adverse effects that worsen outcomes, including hyperglycemia, infection, and the risk of gastrointestinal bleeding.

Start Date01 Jan 2025

Sponsor / Collaborator

St. Anne's University Hospital Brno

[+1]

100 Clinical Results associated with Parecoxib Sodium

Login to view more data

100 Translational Medicine associated with Parecoxib Sodium

Login to view more data

100 Patents (Medical) associated with Parecoxib Sodium

Login to view more data

1,298

Literatures (Medical) associated with Parecoxib Sodium

24 Jan 2025·Journal of Burn Care & Research

Effects of Parecoxib Sodium on Early Cognitive Impairment and Inflammation Levels in Burned Rats

Article

Author: Hu, Guangjun ; Jiang, Xiaoyang ; Zhang, Kun ; Du, Siyu ; Chen, Zhuo

Abstract:

To study the effect of parecoxib sodium in alleviating inflammation in burned rats and restoring cognitive function in burned rats. A total of 30 specific pathogen free grade Sprague–Dawley rats were randomly divided into 6 groups: (1) blank control group (group C), (2) Sham surgery group (group Sham), (3) second-degree burn model (group B), (4) low-dose (1 mg/kg/d) parecoxib sodium (group L + B), (5) medium-dose (10 mg/kg/d) parecoxib sodium (group M + B), and (6) high-dose (20 mg/kg/d) parecoxib sodium (group H + B). ELISA measures inflammatory factors interleukin (IL)-2, IL-6, tumor necrosis factor-alpha (TNF-α), and interferon-gamma (IFN-γ), and cognitive function factors neuron-specific enolase (NSE), cortisol, and S-100β. Combined with water maze and dark-avoidance experiments to further verify the recovery of cognitive function in rats. The contents of IL-2, TNF-α, and IL-6 in group M + B were significantly lower than those in group Sham (P < .05), and the content of IFN-γ was significantly lower than that in group Sham (P < .05). The cognitive markers NSE, S-100β, and cortisol levels in group M + B were significantly higher than those in group Sham at 2 h, 1 d, 5 d, and 10 d after operation (P < .05). In the group M + B dark-avoidance experiment, the number of probes and errors was not significantly different than those in group Sham and group C (P > .05), and the number of times group M + B found a platform in the water maze experiment and crossed the platform was second only to group B and group C. Parecoxib sodium can effectively reduce inflammation in burn rats and promote cognitive recovery in burn rats, and the optimal dose of parecoxib sodium for burn rats is 10 mg/kg.

31 Dec 2024·International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group

Risk factors of chronic kidney disease in cisplatin-based hyperthermia intraperitoneal chemotherapy

Article

Author: Cheng, Chih-Chung ; Yeh, Hung-Chieh ; Chang, Sheng-Chi ; Ho, Chien-Lin ; Su, Pei-Wen

PURPOSE:

Cisplatin is commonly prescribed in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancy. Acute kidney injury (AKI) is regarded as a common complication after HIPEC combined with cytoreductive surgery (CRS). However, post-HIPEC chronic kidney disease (CKD) is scarce and less investigated. This study aims to investigate the incidence of CKD following cisplatin-based HIPEC and to analyse the associated risk factors.

MATERIALS AND METHODS:

From January 2016 to August 2021, a total of 55 patients treated with CRS and cisplatin-based HIPEC for peritoneal carcinomatosis were categorized retrospectively into groups, with and without CKD. Demographics, comorbidity, surgery, postoperative management, and complications were collected to evaluate risk factors for cisplatin-based HIPEC-related CKD. Univariate and multivariate analyses were conducted to confirm the correlation between different variables and CKD occurrence.

RESULTS:

Of the 55 patients, 24 (43.6%) patients developed AKI and 17 (70.8%) patients of these AKI patients progressed to CKD. Multivariate regression analysis identified intraoperative use of parecoxib (Odds Ratio (OR) = 4.39) and intraoperative maximum temperature > 38.5°C (OR = 6.40) as major risk factors for cisplatin-based HIPEC-related CKD occurrence. Though type II diabetes mellitus and intraoperative complications were the independent risk factors of AKI following cisplatin-based HIPEC, but they were not shown in CKD analysis.

CONCLUSION:

Intraoperative use of parecoxib during cisplatin-based HIPEC emerged as a significant risk factor for postoperative CKD. Clinicians should exercise caution in prescribing parecoxib during HIPEC procedures. Additionally, maintaining intraoperative body temperature below 38.5°C might be crucial to mitigate the risk of CKD development. This study underscores the importance of identifying and preventing specific risk factors to improve long-term renal outcomes in patients undergoing cisplatin-based HIPEC.

01 Dec 2024·NEUROPHARMACOLOGY

Increased levels of Escherichia-Shigella and Klebsiella in the gut contribute to the responsivity of placebo analgesia

Article

Author: Liu, Cunming ; Zhang, Xinying ; Hu, Suwan ; Yang, Chun ; Zhang, Qi ; Bu, Yuchen ; Wu, Zifeng ; Wang, Di ; Yang, Siqi ; Huang, Chaoli ; Wang, Yuanyuan

Placebo analgesia is observed in both humans and animals. Given the complexity of placebo analgesia involving a variety of neurobiological, psychological, and psychosocial processes, further investigation into its underlying mechanisms is essential. Gut microbiota has been implicated in the responsivity of placebo analgesia, but its precise role remains unknown and warrants further investigations. Here, we conducted a conditioning training model with chronic inflammatory pain induced by complete Freund's adjuvant (CFA) in mice, associating parecoxib with different cues. Hierarchical clustering analysis of placebo analgesia behaviors was employed to classify mice into responders and non-responders phenotypes. Approximately 40% of CFA mice undergoing conditioning training exhibited placebo analgesia. Notably, placebo analgesia responders displayed reduced anxiety-like behaviors. 16S rRNA results revealed a distinct composition of gut microbiota composition among the control, placebo analgesia non-responders and responders groups. Notably, levels of Escherichia Shigella and Klebsiella in the gut were increased considerably in the placebo analgesia responders as compared to both control and non-responders groups. In conclusion, placebo analgesia responders demonstrated marked analgesia, reduced anxiety-like behaviors, and increased levels of Escherichia-Shigella and Klebsiella, implying a potential linkage between gut microbiota and placebo analgesia.

100 Deals associated with Parecoxib Sodium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D03717	Parecoxib Sodium	M01AH04	DB08439

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Pain, Postoperative	European Union	Pfizer Europe MA EEIG	22 Mar 2002
Pain, Postoperative	Iceland	Pfizer Europe MA EEIG	22 Mar 2002
Pain, Postoperative	Liechtenstein	Pfizer Europe MA EEIG	22 Mar 2002
Pain, Postoperative	Norway	Pfizer Europe MA EEIG	22 Mar 2002

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pain	Phase 3	Australia	Pfizer Inc.	01 Apr 2003
Colic	Phase 3	Italy	Pfizer Inc.	01 Apr 2002
Renal Colic	Phase 3	Italy	Pfizer Inc.	01 Apr 2002

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ILCA2020	Phase 3	Hepatocellular Carcinoma	80	Parecoxib sodium 40 mg	igytdobsnh(uxsdvbrhgy) = axtlynbyee jryjytmeqv (qswobhbcld, 9.8 - 28.2) View more	Positive	13 Sep 2020
				Placebo	igytdobsnh(uxsdvbrhgy) = bxmqcyhzfs jryjytmeqv (qswobhbcld, 8.1 - 19.9) View more
ILCA2020	Not Applicable	Hepatocellular Carcinoma	-	Parecoxib sodium + TAP block	pdeutkmklm(oeoqbiiqum) = No significant differences were found between the two groups related to adverse events xvdevbleut (gpqmzwjbyc ) View more	Positive	13 Sep 2020
NCT01566669 (PCEA, Pubmed \| PLoS One)	Not Applicable	-	240	Parecoxib	evtwtjonrq(refqnjuxkp) = wyawackmps icwzsoaslc (sqkedxrzxa ) View more	Positive	01 Jan 2016
				Placebo	evtwtjonrq(refqnjuxkp) = eascborjpe icwzsoaslc (sqkedxrzxa ) View more
NCT00346268 (PROSTATECTOMY, Pubmed \| BMC Anesthesiol) Manual	Phase 4	Hemorrhage \| Analgesia	105	Morphine+parecoxib	heoevxipkw(tovgnznkje) = lneajdutnl rkrsyazbmy (omtoqwwftu, 24.1) View more	Positive	09 Mar 2015
				Morphine+Placebo	heoevxipkw(tovgnznkje) = vzmfnccteo rkrsyazbmy (omtoqwwftu, 28) View more
NCT00553605 (NAP, CTgov)	Phase 4	Renal Colic	340	Parecoxib (Parecoxib)	ggadqlnbwq(oejskrdsnp) = kynealtzig casltntrkt (hskteanrse, 3.35) View more	-	28 Jan 2013
				Ketoprofen (Ketoprofen)	ggadqlnbwq(oejskrdsnp) = ciiqtujcus casltntrkt (hskteanrse, 3.46) View more
NCT00346268 (PROSTATECTOMY, CTgov)	Phase 4	Pain, Postoperative	105	Parecoxib+Morphine (Parecoxib and Morphine)	podpfihupe(eoyvcpbxqx) = sqxsrzvrjc gdgkjfopev (ugntzpmdev, 16.16) View more	-	28 Oct 2011
				Placebo+Morphine (Placebo and Morphine)	podpfihupe(eoyvcpbxqx) = pdpxrhnmhf gdgkjfopev (ugntzpmdev, 19.99) View more
NCT00455117 (Pubmed \| Br J Anaesth)	Phase 4	Pain, Postoperative	-	Parecoxib 40 mg	qtgyxakrnv(ahefcdetnz) = zavoofwtcc aaqlizsktf (ogfaqvuhre )	Negative	01 Sep 2011
				Placebo	qtgyxakrnv(ahefcdetnz) = rdnfqvuitg aaqlizsktf (ogfaqvuhre )